Pemetrexed pathway-associated germline polymorphisms: A useful tool for treatment individualization?

Journal of Clinical Oncology

Volumn 28, Issue 27, 2010, Pages

  Buikhuisen, Wieneke A ^a   Burgers, Jacobus A ^a   Vincent, Andrew D ^a   Schellens, Jan H M ^a,b   Beijnen, Jos H ^b,c   Smit, Egbert F ^d   Joerger, Markus ^e  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; GAMMA GLUTAMYL HYDROLASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PEMETREXED; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; TUMOR MARKER;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DNA POLYMORPHISM; DRUG COST; EXON; GERM LINE; HUMAN; LETTER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; UNSPECIFIED SIDE EFFECT; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETICS; LUNG TUMOR; MORTALITY; NOTE; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; GLUTAMATES; GUANINE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; PATIENT SELECTION; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77957934316     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.1559     Document Type: Letter

References (8)

1. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 (Pubitemid 41079796)
2. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644, 2003 (Pubitemid 46606305)
4. Asukai Y, Valladares A, Camps C, et al: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: Results for the non-squamous histology population. BMC Cancer 10:26, 2010
5. Klein R, Muehlenbein C, Liepa AM, et al: Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 4:1404-1414, 2009
6. Adjei AA, Mandrekar SJ, Dy GK, et al: Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 28:614-619, 2010
7. Smit EF, Burgers SA, Biesma B, et al: Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27:2038-2045, 2009
8. Leil TA, Endo C, Adjei AA, et al: Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res 67:8772-8782, 2007 (Pubitemid 47437453)